Collaborative Neuroscience Network

Long Beach, California 92845

0 studies enrolling now · 20 studies all time

What they study most

ARCA1 - Autosomal Recessive Cerebellar Ataxia Type 1, Alzheimer Disease, Alzheimer's Disease, Behavioral Variant Frontotemporal Dementia, Depressive Disorder, Major, Driving Impaired, Healthy Participants, Major Depressive Disorder (MDD), Mild Alzheimer's Disease, Opioid Use Disorder, Opioid-related Disorders, Parkinson's Disease

Studies at this site

• A Study of Seltorexant Compared to Quetiapine XR as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy — Completed
• Study to Assess the Safety and Pharmacokinetics of CY6463 in Participants With Stable Schizophrenia — Completed
• A Study in Patients With Major Depressive Disorder — Status unconfirmed
• Open-Label Study of Leuco-methylthioninium Bis(Hydromethanesulfonate) (LMTM) in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD) — Stopped early
• Safety and PK Trial With Injectable ZX003 (Risperidone-SABER®) Compared to Risperdal® Consta® in Stable Schizophrenia — Completed
• Driving Simulation to Assess Non-Sedative Effects of Tolperisone — Completed
• Comparative Bioavailability of Risperidone — Completed
• AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext — Completed
• Study of CAD-1883 for Spinocerebellar Ataxia — Withdrawn before enrolling
• Multiple Dose Safety Study of NPT088 in Patients With Mild to Moderate Probable Alzheimer's Disease — Completed
• Safety, Tolerability, PK and Efficacy of Single Doses of NV-5138 in Healthy Volunteers and Subjects With Treatment-Resistant Depression — Completed
• A Study to Assess the Safety, Tolerability, and Pharmacokinetics of E2730 in Healthy Participants — Completed
• Open-Label Treatment Extension Study — Completed
• Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease — Completed
• DNS-7801 vs. Placebo in Parkinson's Disease — Stopped early
• Safety, Tolerability, and Pharmacokinetics of APN1125 in Subjects With Schizophrenia — Paused
• Study Evaluating Safety, Tolerability, and PK of Multiple Ascending Doses of GC021109 in Subjects With Mild to Moderate Alzheimer's Disease — Completed
• Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier) — Completed
• Multiple Ascending Dose Study of TC-5619 in Healthy Elderly Subjects and Subjects With Alzheimer's Disease — Completed
• An Escalating Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LNK 754 in Elderly Volunteers and in Subjects With Mild Alzheimer's Disease — Completed